86 306

Cited 7 times in

Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer

DC FieldValueLanguage
dc.contributor.author이희승-
dc.contributor.author문도창-
dc.contributor.author정문재-
dc.contributor.author박정엽-
dc.contributor.author송시영-
dc.contributor.author방승민-
dc.contributor.author박용구-
dc.contributor.author이배환-
dc.contributor.author박용구-
dc.contributor.author이배환-
dc.date.accessioned2019-05-07T01:49:28Z-
dc.date.available2019-05-07T01:49:28Z-
dc.date.issued2016-
dc.identifier.issn0513-5796-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/168121-
dc.description.abstractPURPOSE: Erlotinib-gemcitabine combined chemotherapy is considered as the standard treatment for unresectable pancreatic cancer. This study aimed to determine the clinical factors associated with response to this treatment. MATERIALS AND METHODS: This retrospective study included 180 patients with unresectable pancreatic cancer who received ≥2 cycles of gemcitabine-erlotinib combination therapy as first-line palliative chemotherapy between 2006 and 2014. "Long-term response" was defined as tumor stabilization after >6 chemotherapy cycles. RESULTS: The median progression-free survival (PFS) and overall survival (OS) were 3.9 and 8.1 months, respectively. On univariate analysis, liver metastasis (p=0.023) was negatively correlated with long-term response. Locally advanced stage (p=0.017), a history of statin treatment (p=0.01), and carcinoembryonic antigen levels <4.5 (p=0.029) had a favorable effect on long-term response. On multivariate analysis, a history of statin treatment was the only independent favorable factor for long-term response (p=0.017). Prognostic factors for OS and PFS were significantly correlated with liver metastasis (p=0.031 and 0.013, respectively). A history of statin treatment was also significantly associated with OS after adjusting for all potential confounders (hazard ratio, 0.48; 95% confidence interval, 0.26-0.92; p=0.026). CONCLUSION: These results suggest that statins have a favorable effect on "long-term response" to gemcitabine-erlotinib chemotherapy in unresectable pancreatic cancer patients. Statins may have a chemoadjuvant role in stabilizing long-term tumor growth.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherYonsei University-
dc.relation.isPartOfYONSEI MEDICAL JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenocarcinoma/drug therapy*-
dc.subject.MESHAdenocarcinoma/secondary-
dc.subject.MESHAdolescent-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHDeoxycytidine/administration & dosage-
dc.subject.MESHDeoxycytidine/analogs & derivatives-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHErlotinib Hydrochloride/administration & dosage-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHHydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHPancreatic Neoplasms/drug therapy*-
dc.subject.MESHPancreatic Neoplasms/pathology-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSurvival Rate-
dc.subject.MESHYoung Adult-
dc.titleConcomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorDo Chang Moon-
dc.contributor.googleauthorHee Seung Lee-
dc.contributor.googleauthorYong Il Lee-
dc.contributor.googleauthorMoon Jae Chung-
dc.contributor.googleauthorJeong Youp Park-
dc.contributor.googleauthorSeung Woo Park-
dc.contributor.googleauthorSi Young Song-
dc.contributor.googleauthorJae Bock Chung-
dc.contributor.googleauthorSeungmin Bang-
dc.identifier.doi10.3349/ymj.2016.57.5.1124-
dc.contributor.localIdA03349-
dc.contributor.localIdA01354-
dc.contributor.localIdA01354-
dc.contributor.localIdA03602-
dc.contributor.localIdA03602-
dc.contributor.localIdA01647-
dc.contributor.localIdA01647-
dc.contributor.localIdA02035-
dc.contributor.localIdA02035-
dc.contributor.localIdA01786-
dc.contributor.localIdA01786-
dc.contributor.localIdA01578-
dc.contributor.localIdA01578-
dc.contributor.localIdA02791-
dc.contributor.localIdA02791-
dc.contributor.localIdA01578-
dc.contributor.localIdA01578-
dc.contributor.localIdA02791-
dc.contributor.localIdA02791-
dc.relation.journalcodeJ02813-
dc.identifier.eissn1976-2437-
dc.identifier.pmid27401642-
dc.subject.keywordHydroxymethylglutaryl-CoA reductase inhibitors-
dc.subject.keyworderlotinib-
dc.subject.keywordgemcitabine-
dc.subject.keywordpancreatic neoplasms-
dc.contributor.alternativeNameLee, Hee Seung-
dc.contributor.affiliatedAuthor이희승-
dc.contributor.affiliatedAuthor문도창-
dc.contributor.affiliatedAuthor문도창-
dc.contributor.affiliatedAuthor정문재-
dc.contributor.affiliatedAuthor정문재-
dc.contributor.affiliatedAuthor박정엽-
dc.contributor.affiliatedAuthor박정엽-
dc.contributor.affiliatedAuthor송시영-
dc.contributor.affiliatedAuthor송시영-
dc.contributor.affiliatedAuthor방승민-
dc.contributor.affiliatedAuthor방승민-
dc.contributor.affiliatedAuthor박용구-
dc.contributor.affiliatedAuthor박용구-
dc.contributor.affiliatedAuthor이배환-
dc.contributor.affiliatedAuthor이배환-
dc.contributor.affiliatedAuthor박용구-
dc.contributor.affiliatedAuthor박용구-
dc.contributor.affiliatedAuthor이배환-
dc.contributor.affiliatedAuthor이배환-
dc.citation.volume57-
dc.citation.number5-
dc.citation.startPage1124-
dc.citation.endPage1130-
dc.identifier.bibliographicCitationYONSEI MEDICAL JOURNAL, Vol.57(5) : 1124-1130, 2016-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Physiology (생리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.